Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05430009 · ClinicalTrials.gov registry record · Phase 1

Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer

A Phase 1 study of Non-Small Cell Lung Cancer and Liver Metastases, sponsored by VA Ann Arbor Healthcare System.

Recruiting
Registry status
Phase 1
Development phase
12
Enrollment target
1
Study location

NCT05430009: Recruiting Phase 1 study of Non-Small Cell Lung Cancer and Liver Metastases, sponsored by VA Ann Arbor Healthcare System.

NCT05430009 is a Phase 1 study of Non-Small Cell Lung Cancer and Liver Metastases that is actively recruiting participants, run by VA Ann Arbor Healthcare System. The registered enrollment target is 12 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05430009, a Phase 1 study of Non-Small Cell Lung Cancer and Liver Metastases, is actively recruiting participants, sponsored by VA Ann Arbor Healthcare System.

RECRUITING
Registry status
Phase 1
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

Determine the feasibility of liver stereotactic body radiation therapy (SBRT) given in combination with systemic therapy (immune checkpoint inhibitors) in adult patients with metastatic NSCLC with liver metastases.

Interventions

  • DRUG Pembrolizumab
  • RADIATION Liver SBRT

Study Locations (1)

Michigan

  • Veterans Affairs Ann Arbor Healthcare System - Ann Arbor

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2022-06-17
Est. Completion 2026-06-15
Phase Phase 1
VA Ann Arbor Healthcare System

5 total trials

What NCT05430009 shows while recruiting

NCT05430009 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (98% lower).

The record links to 2 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.

NCT05430009 reports a single indexed study location in Michigan.

Frequently Asked Questions

What is clinical trial NCT05430009 about?

NCT05430009 is a clinical study titled "Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer". Determine the feasibility of liver stereotactic body radiation therapy (SBRT) given in combination with systemic therapy (immune checkpoint inhibitors) in adult patients with metastatic NSCLC with liver metastases.

What is the current status of trial NCT05430009?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2022-06-17. Estimated completion is 2026-06-15.

What conditions does trial NCT05430009 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Liver Metastases.

What interventions are being tested in trial NCT05430009?

The interventions under investigation include: Pembrolizumab (DRUG), Liver SBRT (RADIATION).

Who is sponsoring clinical trial NCT05430009?

This trial is sponsored by VA Ann Arbor Healthcare System, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05430009 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05430009's enrollment target sits among peer trials

12 437th of 454 higher than 12 of 454 other Non-Small Cell Lung Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02602769 · 12 participants

    Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

  • NCT02605421 · 12 participants · Phase 2

    Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

  • NCT03311503 · 12 participants · Phase 1

    Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

  • NCT03312556 · 12 participants · NA

    Treatment of Supine Hypertension in Autonomic Failure (CPAP)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05430009, the US trial registry maintained by the National Library of Medicine. NCT05430009 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.